ICML 2025

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Agenda

Medical Materials

12:50 PM

Duration 15mins Room A

Polatuzumab vedotin▼, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase III POLARGO trial

Sancho J-M, Li Z, Vassilakopoulos TP, Viardot A, McMillan A, Dal MS, Pereira J, Kim JS, Qiu L, Batlevi CL, Ibrahim R, Hernandez J, McCall B, Jiang Y, Yan M, Harris W, Musick L, Haioun C, Matasar M

Hematology - Oncology | Diffuse large B cell lymphoma

03:30 PM

Duration 10mins Room A

Fixed duration subcutaneous mosunetuzumab▼ in patients with previously untreated high-tumor burden follicular lymphoma: interim results from the Phase II MorningSun study

Budde LE, Burke JM, Sharman JP, Anz B, Zuniga R, Tun AM, Jani P, Biondo JML, Wu M, Mun Y, Chopra VS, Farighi R, Lin T, Villasboas JC, Flinn IW

Hematology - Oncology | Follicular Lymphoma

10:30 AM

Duration 30mins Lugano, Switzerland

Safety and efficacy of mosunetuzumab▼ subcutaneous maintenance following mosunetuzumab▼ plus lenalidomide induction therapy in previously untreated follicular lymphoma

Eyre TA, Cordoba R, Patel K, Serna A, Houot R, Bishton M, Zhang H-L, Zou L, Galvez-Carvajal L, Osborne W, Bachy E, Thieblemont C, Knapp A, Sit J, Chang N, Chen V, Penuel E, Wei MC, Purev E, Morschhauser F

Hematology - Oncology | Follicular Lymphoma

Duration 30mins Lugano, Switzerland

Fixed-duration subcutaneous mosunetuzumab▼ in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with high-risk features: pivotal Phase II study update

Sehn LH, Budde LE, Assouline S, Giri P, Kuruvilla J, Schuster SJ, Yoon S-S, Fay K, Hess G, Dreyling M, Gutierrez NC, Cybulski E, Kwan A, Penuel E, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Bartlett NL

Hematology - Oncology | Follicular Lymphoma

Duration 30mins Lugano, Switzerland

Machine learning based unsupervised multimodal analysis identifies patient subsets associated with response to mosunetuzumab ▼ in relapsed/refractory NHL

Hamidi H, Diaz G, Tracy S, Yin S, Wei MC, Penuel E

Hematology - Oncology | Non Hodgkin Lymphoma

01:00 PM

Duration 10mins Auditorium

Glofitamab▼ plus R-ICE or as monotherapy in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma: updated analysis from the iMATRIX-GLO study

Minard-Colin V, Vinti L, San Simon AR, Kang HJ, Ducassou S, Gamel K, Wulff J, Chohan S, Hallal M, Negrecea R, Wulff B, Burkhardt B

Hematology - Oncology | Non Hodgkin Lymphoma

02:45 PM

Duration 15mins Room A

Fixed-duration outpatient subcutaneous mosunetuzumab▼ + polatuzumab vedotin▼ shows robust efficacy in a Phase II study of relapsed/refractory post-BTKi mantle cell lymphoma

Budde LE, Kamdar M, Assouline S, Ghosh N, Naik S, Nakhoda SK, Chavez J, Ollila TA, Hodson D, Modi D, Bastos-Oreiro M, Ead W, To I, Pham S, Wang J, Wu H, Makadia S, Batlevi CL, Wei MC, Wang ML

Hematology - Oncology | Mantle Cell Lymphoma

03:35 PM

Duration 10mins Polivalente Room

Glofitamab▼+R-CHOP in patients with previously untreated large B-cell lymphoma defined as high risk by circulating tumor DNA (ctDNA) dynamics: primary results

Nijland M, Jardin F, Haioun C, Wrobel T, Joergensen J, Bastos-Oreiro M, Mou E, Lopez JM, Budde LE, Bartlett N, Zaucha J, Garcia-Sancho AM, Ursich E, Kirk S, Jiang Y, Berthier A, Tandon M, Doral M, Falchi L

Hematology - Oncology | Diffuse large B cell lymphoma

10:30 AM

Duration 30mins Lugano, Switzerland

Mosunetuzumab▼ demonstrates durable clinical benefit in patients (pts) with complete response (CR) and high-risk relapsed/refractory (R/R) follicular lymphoma (FL)

Cheah CY, Bartlett NL, Matasar M, Schuster SJ, Assouline S, Sehn LH, Kuruvilla J, Giri P, Shadman M, Ku M, Hess G, Gregory GP, Kim WS, Wei MC, Yin S, Sit J, Tracy S, Sabalvaro F, Penuel E, Budde LE

Hematology - Oncology | Follicular Lymphoma

Duration 30mins Lugano, Switzerland

Glofitamab ▼ combined with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): final results from the NP40126 study

Topp MS, Tani M, Dickinson M, Ghosh N, Santoro A, Pinto A, Bosch F, Fox CP, Guillermo AL, Gastinne T, Viardot A, Townsend W, Cordoba R, Tilly H, Baumlin P, Berthier A, Kirk S, Wu C, Barrett M, Morschhauser F

Hematology - Oncology | Diffuse large B cell lymphoma

Duration 30mins Lugano, Switzerland

Genomic profiling of extranodal (EN) disease in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A combined analysis of POLARIX and GOYA

Lue JK, Morschhauser F, Tilly H, Lenz G, Jardin F, Herrera AF, Sharman JP, Flowers CR, Friedberg JW, Trněný M, Herbaux C, Yan M, Chohan S, Sugidono M, Wang L, Jiang Y, Batlevi CL, Leung W, Harris W, Salles G, Sehn LH

Hematology - Oncology | Diffuse large B cell lymphoma

Duration 30mins Lugano, Switzerland

Real-world safety and efficacy of Pola-R-CHP in patients with previously untreated DLBCL: analysis of 500 patients in the POLASTAR study

Nakamura N, Rai S, Sawa H, Miyawaki K, Satake A, Suzuki R, Fujiwara Y, Nagate Y, Ota S, Fujino T, Goto H, Fukuhara N, Sakata-Yanagimoto M, Izutsu K, Nishikori M, Shibayama H, Kumode T, Ennishi D, Shimose T, Inubashiri N, Matsumura I, Akashi K, Kato K

Hematology - Oncology | Diffuse large B cell lymphoma

Duration 30mins Lugano, Switzerland

Five-year analysis of an Asia subpopulation with previously untreated DLBCL confirms Pola-R-CHP benefit on outcomes: the POLARIX study

Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, Ogawa Y, Shin H-J, Kim WS, Cao J, Eom HS, Yoon DH, Tsai XC-H, Gau J-P, Maruyama D, Zhang L, Song Y, Yang Y, Li W, Huang H, Okumura H, Salles G, Sehn LH, Bu L, Jiang Y, Chohan S, Sugidono M, Batlevi CL, Yan M, Xu C, Huang S, Li W, Zhang Y, Zhu J, Izutsu K

Hematology - Oncology | Diffuse large B cell lymphoma

12:30 PM

Duration 15mins Room A

Glofitamab▼ plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO

Abramson JS, Ku M, Hertzberg M, Fox CP, Herbaux C, Huang H-Q, Yoon DH, Kim WS, Zhang H, Abdulhaq H, Townsend W, Mulvihill E, Orellana-Noia V, Ta R, Huang H, Kellemeijn MJ, Belousov A, Bottos A, Lundberg L, Gregory GP

Hematology - Oncology | Diffuse large B cell lymphoma

02:30 PM

Duration 15mins Lugano, Switzerland

Mosunetuzumab▼ plus polatuzumab vedotin is superior to R-GemOx in transplant-ineligible patients with R/R LBCL: primary results of the Phase III SUNMO trial

Westin J, Zhang H, Kim W, Fogliatto LM, Maruyama D, Farias DLC, Norasetthada L, Hong H, Ozcan M, Jeon Y-W, Pavlovsky A, Goto H, Olszewski A, Shah N, Hu B, Yin S, Janousek M, Wang J, Batlevi CL, Wei MC, Budde E

Hematology - Oncology | Diffuse large B cell lymphoma

Coming soon

I am a healthcare professional

Notice

Cookies

External site

ICML 2025